A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

Summary

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid plus Long-Acting β2-Agonist

Timeline

Start

2016-11-11

Primary completion

2018-01-19

Completion

2018-01-19

Outcome

Outcome not reported

Stopped: “The study was terminated due to the discontinuation of the tralokinumab asthma program (as per the results of the Phase III study \[D2210C00008\])”

Publications

• Panettieri RA Jr, Wang M, Braddock M, Bowen K, Colice G. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018 Mar 1;10(6):473-490. doi: 10.2217/imt-2017-0191. Epub 2018 Mar 14.

Drugs

Indications